Kiora Pharmaceuticals Inc - Asset Resilience Ratio
Kiora Pharmaceuticals Inc (KPRX) has an Asset Resilience Ratio of 41.06% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KPRX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2025)
This chart shows how Kiora Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Kiora Pharmaceuticals Inc (KPRX) total assets.
Liquid Assets Composition Over Time
This chart breaks down Kiora Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Kiora Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.76 Million | 41.06% |
| Total Liquid Assets | $9.76 Million | 41.06% |
Asset Resilience Insights
- Very High Liquidity: Kiora Pharmaceuticals Inc maintains exceptional liquid asset reserves at 41.06% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kiora Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Kiora Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Kiora Pharmaceuticals Inc (2023–2025)
The table below shows the annual Asset Resilience Ratio data for Kiora Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.60% | $8.39 Million | $24.25 Million | -28.44pp |
| 2024-12-31 | 63.04% | $23.00 Million | $36.48 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $13.71 Million | -- |
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also deve… Read more